Marquette Asset Management’s Metagenomi Therapeutics MGX Stock Holding History

Marquette Asset Management’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$85.8K	Buy	+72,121	New	+$96.5K	0.01%	140
2025 Q1	–	Sell	-51,080	Closed	-$184K	–	203
2024 Q4	$184K	Buy	+51,080	New	+$123K	0.03%	94

Marquette Asset Management's MGX Position: Q2 2026 in Review

Marquette Asset Management opened a new position in Metagenomi Therapeutics (MGX) in Q2 2026: 72,121 shares worth $85.8K. The stake represents 0.01% of the portfolio and ranks #140 among its holdings. This is a return to the name: Marquette Asset Management previously reported a position in MGX as recently as Q4 2024.

Marquette Asset Management first reported a position in MGX in Q4 2024 and has held it in 2 quarters since. The position peaked at $184K in Q4 2024. 1 fund tracked by Wall St. Rank holds MGX as of Q2 2026.

Marquette Asset Management held 72,121 shares of Metagenomi Therapeutics worth $85.8K as of Q2 2026.
Metagenomi Therapeutics was a new Marquette Asset Management position in Q2 2026.
Metagenomi Therapeutics made up 0.01% of Marquette Asset Management's portfolio in Q2 2026, its #140 holding.
Marquette Asset Management first reported a position in Metagenomi Therapeutics in Q4 2024 and has held it in 2 quarters since.
Marquette Asset Management's Metagenomi Therapeutics position peaked at $184K in Q4 2024.
1 fund tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Marquette Asset Management's 13F filing for Q2 2026, filed 9 Jul 2026.